SCHEMBL522189

SCHEMBL522189

Fc1cccc(OBOc2cccc(F)c2F)c1F

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 7/20 0.46
SLC6A4 P31645 6/20 0.46
SLC6A3 Q01959 5/20 0.46
CES2 O00748 2/20 0.37
CES1 P23141 2/20 0.37
BCHE P06276 1/20 0.37
TRPA1 O75762 1/20 0.36
HTR1A P08908 2/20 0.33
NFE2L2 Q16236 1/20 0.31
HRH1 P35367 1/20 0.31
RHEB Q15382 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
FFAR1 O14842 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MAPT P10636 1/20 0.30
CRHBP P24387 1/20 0.30
CRHR2 Q13324 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31317053 0.82 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CES2CES1
SCHEMBL11940797 0.82 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CES2CES1
SCHEMBL106795 0.82 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CES2CES1
SCHEMBL290116 0.80 L3MBTL1 (0.41) SLC6A2SLC6A3HTR1ANFE2L2RHEB
SCHEMBL288166 0.78 CES2 (0.34) CES2CES1
SCHEMBL518108 0.77 CA1 (0.44) NFE2L2L3MBTL1TDP1KDM4EMAPT
SCHEMBL521826 0.77 MRGPRX4 (0.40) SLC6A2SLC6A4SLC6A3HTR1A
SCHEMBL14237478 0.77 SLC6A2 (0.33) SLC6A2SLC6A4SLC6A3HTR1A
SCHEMBL2784082 0.77 ACHE (0.36) SLC6A2SLC6A4SLC6A3TRPA1HTR1A
SCHEMBL14719203 0.77 ALB (0.41) CES2CES1L3MBTL1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-30 US disclosed
EP-4514777-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-03-05 EP disclosed
US-20250059207-A1 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS 858 THERAPEUTICS, INC. 2025-02-20 US disclosed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 WO disclosed
WO-2023129933-A2 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS 858 THERAPEUTICS, INC. (US) 2023-07-06 WO disclosed
EP-3276697-B1 ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC DEVICE AND COMPOUND IDEMITSU KOSAN CO (JP) 2020-08-26 EP disclosed
US-10547009-B2 Organic electroluminescent element, electronic device and compound IDEMITSU KOSAN CO., LTD. (JP) 2020-01-28 US disclosed
EP-2949655-B1 REACTION CATALYST FOR CROSS COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND HOKKO CHEM IND CO (JP) 2019-05-15 EP disclosed
US-10246422-B2 Heterocyclic compounds and use thereof in medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-04-02 US disclosed
CN-108884043-A Substituted piperidine compounds and uses thereof 武田药品工业株式会社 2018-11-23 CN disclosed
WO-2001029012-A2 BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-04-26 WO disclosed
WO-2000077001-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES DU PONT PHARMACEUTICALS COMPANY (US) 2000-12-21 WO disclosed
US-5702642-A ACRYLIC ESTER POLYMERS; BRIGHTNESS IN ABSENCE OF ELECTRIC VOLTAGE SHARP KABUSHIKI KAISHA (JP) 1997-12-30 US disclosed
US-5645760-A Polymeric compounds, and liquid crystal element using the same SHARP KABUSHIKI KAISHA (JP) 1997-07-08 US disclosed
EP-0637624-B1 Antiferroelectric liquid crystal compound SHOWA SHELL SEKIYU (JP) 1996-09-25 EP disclosed
US-5543075-A ANISOTROPIC GEL CONTAINING LIQUID CRYSTAL POLYMER WHICH FORMS PERMANENTLY ORIENTED NETWORK IN LOW MOLECULAR WEIGHT DIELECTRIC LIQUID CRYSTALLINE MATERIAL, DISPLAY CELLS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1996-08-06 US disclosed
US-5417885-A Antiferroelectric liquid crystal compound SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) 1995-05-23 US disclosed
EP-0637624-A1 Antiferroelectric liquid crystal compound Showa Shell Sekiyu Kabushiki Kaisha (JP) 1995-02-08 EP disclosed
EP-0615630-A1 LIQUID CRYSTALLINE MATERIAL MERCK PATENT GmbH (DE) 1994-09-21 EP disclosed
WO-1994008268-A1 LIQUID CRYSTALLINE MATERIAL MERCK PATENT GMBH (DE) 1994-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SCNN1B, SCN1B, SCN2B SLC6A2 51/4885SLC6A4 146/4885SLC6A3 182/4885
US-20250059207-A1 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, METTL16, TPMT SLC6A2 1229/4885SLC6A4 744/4885SLC6A3 374/4885
US-10246422-B2 Heterocyclic compounds and use thereof in medicine and in cosmetics MC1R, BDKRB2, CCKBR SLC6A2 1286/4885SLC6A4 1556/4885SLC6A3 2325/4885
US-10547009-B2 Organic electroluminescent element, electronic device and compound LEF1, FRG1, CTNNA1 SLC6A2 3139/4885SLC6A4 3597/4885SLC6A3 3879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.